[ad_1]
New Delhi: The number of Bangladeshis coming to India for treatment has declined by 50 per cent since the beginning of the Covid-19 pandemic. Recent political developments In that country, Chief Hospital Official Chens told ET.
Industry officials also fear that business disruptions caused by the political crisis could lead to losses. India’s Pharma Exports In Bangladesh, which is a growing market for them.
India has come to the top position Destinations for medical tourists from Bangladeshis, with a large number of patients opting for affordable and cost-effective options High quality treatment in Indian hospitals.
“The Ongoing political crisis The Covid-19 pandemic in Bangladesh has affected patient flow to our hospitals,” a spokesperson said. Fortis HealthcareWhich runs a chain of hospitals.
He said many patients have cancelled or postponed their travel plans, leading to a 50 per cent reduction in the number of such patients in some hospitals. He hoped that “this will gradually improve as the situation in Bangladesh stabilizes.”
A hospital official, who asked not to be named, said the number of patients coming from Bangladesh was rising steadily. He said some hospital chains had the largest number of patients from Bangladesh, adding: “They must have been severely affected.”
An official from the international marketing team of one of the largest hospital chains told ET that hospitals are witnessing huge fluctuations. Decreasing trend in patients He feared a further decline in the number of people coming from Bangladesh.
“We have seen Decrease in the number of patients “The number of patients coming to the hospital from Bangladesh has reduced in the last few weeks. There has been a reduction of about 20 percent since the unrest began,” this executive said. Another executive of a large hospital chain said they have already seen a 5 percent drop in revenue and a 30 percent drop in the number of patients. “Also, new patients are not coming,” he said.
Meanwhile, pharma experts fear disruption in the sector. 30 per cent of total active pharma production comes from Bangladesh. drug paraphernalia And the related raw materials will be imported from India.
“Any crisis impacting the trade could lead to supply delays, increase in costs or even disruptions in drug availability,” said an industry official.
He said that all major pharma companies and medium and small enterprises are likely to be affected.
[ad_2]
Source link